{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:45:24Z","timestamp":1789051524398,"version":"build-2803163510"},"reference-count":14,"publisher":"Georg Thieme Verlag KG","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Therapie mit Eisenpr\u00e4paraten\u2002Mit PIVOTAL erschien 2018 die erste kardiovaskul\u00e4re Endpunktstudie zur Eisensubstitution bei Dialysepatienten, die eine prognostische \u00dcberlegenheit einer Hochdosiseisentherapie gegen\u00fcber einer restriktiveren Eisenapplikation aufzeigte. Mit AFFIRM-AHF, IRONMAN, FAIR-HF2 und HEART-FID \u00fcberpr\u00fcfen aktuell gleich 4 Studien die Bedeutung einer intraven\u00f6sen Eisenapplikation auf kardiovaskul\u00e4re Endpunkte bei Patienten mit Herzinsuffizienz.<\/jats:p><jats:p>\n          Ausblick\u2002HIF-Stabilisatoren erlauben eine orale An\u00e4mie-Behandlung bei chronischer Nierenerkrankung. Erste klinische Studien zeigten eine \u201eNichtunterlegenheit\u201c von HIF-Stabilisatoren gegen\u00fcber der Behandlung mittels rekombinanten Erythropoetins (EPO)\/Erythropoese-stimulierenden Agenzien (ESA) in Bezug auf den H\u00e4moglobinanstieg. Finale Ergebnisse gro\u00dfer Studien mit kardiovaskul\u00e4ren Endpunkten sind aktuell noch ausstehend. In diesen Studien muss das Sicherheitsprofil von HIF-Stabilisatoren \u00fcberpr\u00fcft werden, da HIF-Stabilisatoren die Transkription zahlreicher Gene auch jenseits der H\u00e4matopoese ver\u00e4ndern. In der klinischen Kardiologie spielen HIF-Stabilisatoren aktuell (noch) keine Rolle. Unter der Therapie mittels SGLT-II-Inhibitoren konnte ein Anstieg des H\u00e4matokrits beobachtet werden, welcher sich nicht allein durch diuretische Effekte erkl\u00e4ren l\u00e4sst. Die genaue pharmakodynamische Wirkweise ist noch offen.<\/jats:p>","DOI":"10.1055\/a-1133-7849","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T23:48:40Z","timestamp":1606780120000},"page":"1775-1780","source":"Crossref","is-referenced-by-count":4,"title":["An\u00e4mie und Eisenmangel \u2013 Behandlungsoptionen bei\u00a0chronischer Nierenerkrankung und chronischer Herzinsuffizienz"],"prefix":"10.1055","volume":"145","author":[{"given":"Insa E.","family":"Emrich","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Klinik f\u00fcr Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Klinik f\u00fcr Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar H.","family":"Heine","sequence":"additional","affiliation":[{"name":"Agaplesion Markus-Krankenhaus, Medizinische Klinik II, Frankfurt am Main"},{"name":"Universit\u00e4t des Saarlandes, Medizinische Fakult\u00e4t, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018","volume":"71","author":"S Fishbane","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies","volume":"138","author":"I S Anand","year":"2018","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1525-139X.2008.00423.x","article-title":"From anemia trials to clinical practice: Understanding the risks and benefits when setting goals for therapy","volume":"21","author":"D W Coyne","year":"2008","journal-title":"Semin Dial"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1681\/ASN.2015111232","article-title":"Epoetin alfa and outcomes in dialysis amid regulatory and payment reform","volume":"27","author":"G M Chertow","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron Deficiency in Heart Failure: An Overview","volume":"7","author":"S von Haehling","year":"2019","journal-title":"JACC Hear Fail"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"I C Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ejhf.229","article-title":"The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study","volume":"17","author":"P Ponikowski","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.jacc.2018.03.448","article-title":"High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia","volume":"71","author":"R St\u00f6hr","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MNH.0000000000000617","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease","volume":"29","author":"Y Kurata","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"N Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"N Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"ref13","first-page":"762","article-title":"Antidiabetic SGLT-2 inhibitors prevent progression of chronic kidney disease","volume":"145","author":"G H Heine","year":"2020","journal-title":"Dtsch Med Wochenschr"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"H J Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"C David Mazer","year":"2020","journal-title":"Circulation"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1133-7849.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T23:49:31Z","timestamp":1606780171000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1133-7849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":14,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2020,11,30]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1133-7849","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}